Prestige Consumer Healthcare Inc. (PBH): Price and Financial Metrics


Prestige Consumer Healthcare Inc. (PBH): $53.18

-0.24 (-0.45%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

PBH POWR Grades


  • PBH scores best on the Value dimension, with a Value rank ahead of 88.73% of US stocks.
  • PBH's strongest trending metric is Value; it's been moving down over the last 31 weeks.
  • PBH's current lowest rank is in the Momentum metric (where it is better than 11.83% of US stocks).

PBH Stock Summary

  • Of note is the ratio of Prestige Consumer Healthcare Inc's sales and general administrative expense to its total operating expenses; 72.9% of US stocks have a lower such ratio.
  • For PBH, its debt to operating expenses ratio is greater than that reported by 84.11% of US equities we're observing.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for PBH comes in at 9.88% -- higher than that of 79.7% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Prestige Consumer Healthcare Inc, a group of peers worth examining would be EPRT, NRC, NVEC, JKHY, and INPX.
  • PBH's SEC filings can be seen here. And to visit Prestige Consumer Healthcare Inc's official web site, go to www.prestigebrands.com.

PBH Valuation Summary

  • In comparison to the median Healthcare stock, PBH's price/sales ratio is 22.22% lower, now standing at 2.8.
  • Over the past 200 months, PBH's EV/EBIT ratio has gone up 880.1.
  • Over the past 200 months, PBH's price/earnings ratio has gone up 75.5.

Below are key valuation metrics over time for PBH.

Stock Date P/S P/B P/E EV/EBIT
PBH 2019-01-10 1.6 1.4 4.7 17.3
PBH 2017-11-29 2.5 2.7 22.3 16.1
PBH 2017-09-18 2.9 3.1 24.8 17.7
PBH 2010-10-01 1.6 1.5 14.8 9.6
PBH 2006-07-03 1.7 1.2 19.0 11.7
PBH 2006-06-21 1.7 1.2 19.1 11.7

PBH Growth Metrics

  • Its year over year price growth rate is now at 14.56%.
  • The 5 year price growth rate now stands at -16.53%.
  • The 3 year revenue growth rate now stands at 21.03%.
Over the past 67 months, PBH's revenue has gone up $157,516,000.

The table below shows PBH's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-03-31 943.365 235.607 164.682
2020-12-31 956.839 232.646 166.214
2020-09-30 959.603 241.417 163.399
2020-06-30 960.25 239.501 152.062
2020-03-31 963.01 217.124 142.281
2019-12-31 952.801 211.845 -34.039

PBH Price Target

For more insight on analysts targets of PBH, see our PBH price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $54.75 Average Broker Recommendation 1.58 (Moderate Buy)

PBH Stock Price Chart Interactive Chart >

Price chart for PBH

PBH Price/Volume Stats

Current price $53.18 52-week high $53.88
Prev. close $53.42 52-week low $32.19
Day low $52.88 Volume 247,800
Day high $53.75 Avg. volume 390,705
50-day MA $51.83 Dividend yield N/A
200-day MA $43.40 Market Cap 2.65B

Prestige Consumer Healthcare Inc. (PBH) Company Bio


Prestige Brands Holdings markets and distributes brand name over-the-counter health-care and household products throughout the U.S., Canada, Australia, and in certain other international markets. Core brands include Monistat women's health products, Nix lice treatments, Chloraseptic sore throat treatments, Compound W wart treatments, Clear Eyes eye care products, Little Remedies pediatric products, The Doctor's NightGuard dental protector, Efferdent denture care products, Luden's throat drops, Dramamine motion sickness treatments, BC and Goody's headache remedies, Beano gas prevention, Debrox earwax remover, and in Canada, Gaviscon antacid. The company was founded in 1996 and is based in Tarrytown, New York.

PBH Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$53.18$37.29 -24%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Prestige Consumer Healthcare Inc. To summarize, we found that Prestige Consumer Healthcare Inc ranked in the 47th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 24%. The most interesting components of our discounted cash flow analysis for Prestige Consumer Healthcare Inc ended up being:

  • The compound growth rate in the free cash flow of Prestige Consumer Healthcare Inc over the past 5.76 years is 0.04%; that's better than only 23.43% of cash flow producing equities in the Healthcare sector, where it is classified.
  • The business' balance sheet suggests that 38% of the company's capital is sourced from debt; this is greater than 74.49% of the free cash flow producing stocks we're observing.
  • Prestige Consumer Healthcare Inc's weighted average cost of capital (WACC) is 9%; for context, that number is higher than only 13.08% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-26%
1%-25%
2%-24%
3%-24%
4%-23%
5%-22%

Want more companies with a valuation profile/forecast similar to that of Prestige Consumer Healthcare Inc? See EGRX, MEDP, MMSI, AZN, and ADUS.


PBH Latest News Stream


Event/Time News Detail
Loading, please wait...

PBH Latest Social Stream


Loading social stream, please wait...

View Full PBH Social Stream

Latest PBH News From Around the Web

Below are the latest news stories about Prestige Consumer Healthcare Inc that investors may wish to consider to help them evaluate PBH as an investment opportunity.

Prestige Brands (PBH) Reports Next Week: What to Expect

Prestige Brands (PBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 29, 2021

Europe Artificial Tears Market Size, Share, Demand, Analysis and Forecast To 2028 |Alcon Inc., OASIS Medical, AbbVie Inc., Bayer AG, Prestige Consumer Healthcare Inc., Santen Pharmaceutical Co., Ltd., Bausch Health Companies Inc. and more

The Artificial tears market in Europe is expected to grow from US$ 546.0 million in 2021 to US$ 816.9 million by 2028; it is estimated to grow at a CAGR of 5.9% from 2021 to 2028. The Business Market Insights provides

OpenPR | July 27, 2021

Investors Who Bought Prestige Consumer Healthcare (NYSE:PBH) Shares Three Years Ago Are Now Up 46%

Low-cost index funds make it easy to achieve average market returns. But across the board there are plenty of stocks...

Yahoo | July 23, 2021

Prestige Brands Stock Notches A Healthy 84 RS Rating

On Tuesday, Prestige Brands stock hit an important technical milestone, with its Relative Strength Rating climbing to 84, up from 80 the day before. An over-80 RS Rating for Prestige Brands makes it a stock to watch. Is Prestige Brands Stock A Buy?

Yahoo | July 20, 2021

Prestige Consumer Healthcare In Consensus Indicates Potential 5.6% Upside

Prestige Consumer Healthcare In with ticker code (PBH) have now 4 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 59 and 52 with a mean TP of 54.75. With the stocks previous close at 51.86 this would indicate that there is a potential upside of 5.6%. The day 50 moving average is 51.63 and the 200 day moving average is 45.22. The market cap for the company is $2,586m. You can visit the company''s website by visiting: /> [stock_market_widget type="chart" symbol="PBH" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthca...

DirectorsTalk | July 16, 2021

Read More 'PBH' Stories Here

PBH Price Returns

1-mo 2.68%
3-mo 15.36%
6-mo 25.81%
1-year 36.78%
3-year 42.58%
5-year 4.81%
YTD 52.51%
2020 -13.90%
2019 31.15%
2018 -29.59%
2017 -14.76%
2016 1.20%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8459 seconds.